Coherus Oncology Inc 2025年季度报告

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedJune 30, 2025 Commission File Number:001-36721 Coherus Oncology,Inc. (Exact Name of Registrant as Specified in Its Charter) (Registrant’s Telephone Number, Including Area Code) Securies registered pursuant to Secon12(b)of the Act: Indicate by check mark whether the registrant (1)hasfiled all reports required to befiled by Secon13 or15(d)of the Securies Exchange Act of 1934 during the preceding 12months (or for such shorter period that theregistrant was required tofile such reports), and (2)has been subject to suchfiling requirements for the past90days.Yes☒No☐ Indicate by check mark whether the registrant has submied electronically every Interacve Data File requiredto be submied pursuant to Rule405 of Regulaon S-T (§232.405 of this chapter) during the preceding 12months(or for such shorter period that the registrant was required to submit suchfiles).Yes☒No☐ Indicate by check mark whether the registrant is a large acceleratedfiler, an acceleratedfiler, a non-acceleratedfiler, a smaller reporng company, or an emerging growth company. See the definions of “largeacceleratedfiler,” “acceleratedfiler,” “smaller reporng company,” and “emerging growth company” in Rule12b-2 ofthe Exchange Act. Largeacceleratedfiler☐Non-acceleratedfiler☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extendedtransion period for complying with any new or revisedfinancial accounng standards provided pursuant toSecon13(a)of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the ExchangeAct).Yes☐No☒ COHERUS ONCOLOGY,INC.FORM10-Q FOR THE QUARTER ENDED JUNE 30, 2025TABLE OF CONTENTS PageCAUTIONARY NOTEREGARDING FORWARD LOOKING STATEMENTS3PARTIFINANCIAL INFORMATION5ITEM1Unaudited Condensed Consolidated Financial Statements5Condensed Consolidated Balance Sheets5Condensed Consolidated Statements of Operaons6Condensed Consolidated Statements of Comprehensive Income (Loss)7Condensed Consolidated Statements of Stockholders’ Equity (Deficit)8Condensed Consolidated Statements of Cash Flows9Notesto Condensed Consolidated Financial Statements10ITEM2Management’s Discussion and Analysis of Financial Condion and Results ofOperaons28ITEM3Quantave and Qualitave Disclosure About Market Risk40ITEM4Controls and Procedures40PARTIIOTHER INFORMATION41ITEM1.Legal Proceedings41ITEM1A.Risk Factors41ITEM2Unregistered Sales of Equity Securies and Use of Proceeds, and Issuer Purchases ofEquity Securies92ITEM3Defaults Upon Senior Securies92ITEM4Mine Safety Disclosures92ITEM5Other Informaon92ITEM6.Exhibits93 LOQTORZI®, whether or not appearing in large print or with the trademark symbol, is aregistered trademark of Coherus. Trademarks and trade names of other companies appearingin this Quarterly Report on Form 10-Q are, to the knowledge of Coherus, the property of theirrespecve owners. CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form10-Q contains forward-looking statementsregarding futureevents and our future results that are subject to the safe harbors created under the Securies Act of1933, as amended (the “Securies Act”), and the Securies Exchange Act of 1934, as amended (the“Exchange Act”).Any statements contained herein that are not statements of historical factscontained in this Quarterly Report on Form10-Q may be deemed to be forward-looking statements.In some cases, you can idenfy forward-looking statements by words such as “aim,” “ancipate,”“assume,” “aempt,” “believe,” “contemplate,” “connue,” “could,” “due,” “esmate,” “expect,”“goal,” “intend,” “may,” “objecve,” “plan,” “predict,” “potenal,” “seek,” “should,” “strive,” “target,”“will,” “would” and other similar expressions that are predicons of or indicate future events andfuture trends, or the negave of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: ●whether we will be able to connue to maintain or increase sales for our product;●our expectaons regarding our ability to develop and commercialize our productcandidates;●our ability to maintain regulatory approval for our product and our ability to obtain andmaintain regulatory approval of our product candidates, if and when approved;●ourexpectaons regarding government and third-party payer coverage andreimbursement;●our ability to manufacture our product and product candidates in conformity withregulatory requirements and to scale up manufacturing capacity of our product andproduct candidates for commercial supply;●our reliance on third-party contract manufacturers to supply our product candidates andproduct for us;●our expectaons regarding the potenal market size and the size of the paentpop